[A18-07] Ribociclib (breast cancer) – Addendum to Commission A17-45
Last updated 19.03.2018
Commission awarded on 22.01.2018 by the Federal Joint Committee (G-BA).
Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Unchanged conclusion compared with dossier assessment A17-45
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A17-45||Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|